Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: A population-based cohort study

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 120, Issue 10, 2013, Pages 1260-1268

  Zorzi, M ^a   Del Mistro, A ^a   Farruggio, A ^b   De'Bartolomeis, L ^b   Frayle Salamanca, H ^a   Baboci, L ^a   Bertazzo, A ^b   Cocco, P ^b   Fedato, C ^a   Gennaro, M ^b   Marchi, N ^b   Penon, M G ^b   Cogo, C ^a   Ferro, A ^b  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b Piedmont Cancer Registry Province of Biella   (Italy)

Author keywords

Cervical cancer screening; HPV DNA test; human papillomavirus

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; COHORT ANALYSIS; COLPOSCOPY; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; INTERMETHOD COMPARISON; ITALY; PAPANICOLAOU TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; SQUAMOUS CELL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

CERVICAL CANCER SCREENING; HPV DNA TEST; HUMAN PAPILLOMAVIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; COHORT STUDIES; COLPOSCOPY; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; ITALY; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; REFERRAL AND CONSULTATION; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84882286338     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.12272     Document Type: Article

References (29)

1. Arbyn M, Ronco G, Meijer CJLM, Naucler P,. Trials comparing cytology with human papillomavirus screening. Lancet Oncol 2009; 10: 935-6.
2. Arbyn M, Ronco G, Anttila A, Meijer CJLM, Poljak M, Ogilvie G, et al. Evidence regarding Human Papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30S: F88-99.
3. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11: 249-57.
4. Bulkmans N, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papilllomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-72.
5. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolau tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-97.
6. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009; 10: 672-82.
7. Confortini M, Giorgi Rossi P, Barbarino P, Passarelli AM, Orzella L, Tufi MC,. Screening for cervical cancer with the human papillomavirus test in an area of central Italy with no previous active cytological screening programme. J Med Screen 2010; 17: 79-86.
8. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European guidelines for quality assurance in cervical cancer screening. Second edition-summary document. Ann Oncol 2010; 21: 448-58.
9. Coleman D, Day N, Douglas G, Farmery E, Lynge E, Philip J, et al. European guidelines for quality assurance in cervical cancer screening. Europe against cancer programme. Eur J Cancer 1993; 29A (Suppl 4): S1-38.
10. Gruppo Italiano Screening Citologico (GISCi). Raccomandazioni sul test HR-HPV come test di screening primario e rivisitazione del ruolo del Pap test. Belluno: Evidenzia, 2010. pp. 19 (Italian). [www.gisci.it/documenti/documenti- gisci/documento-hpv.pdf]. Accessed 17 September 2012.
11. Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, et al. Health Technology Assessment Report: HPV DNA based primary screening for cervical cancer precursors. Epidemiol Prev 2012; 36 (Suppl 1): e1-72.
12. Solomon D, Davey DD, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-9.
13. Herbert A, Bergeron C, Wiener H, Schenck U, Klinkhamer P, Bulten J, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology. Cytopathology 2007; 18: 213-9.
14. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, et al. Age-specific evaluation of primary Human Papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009; 101: 1612-23.
15. Giorgi Rossi P, Bisanzi S, Paganini I, Di Iasi A, Angeloni C, Scalisi A, et al. Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study. BMC Infect Dis 2010; 10: 214.
16. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, et al. Human papillomavirus testing and liquid-based cytologyzr in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006; 7: 545-53.
17. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, et al. Human Papillomavirus testing and liquid-based cytology in primary cervical screening: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 765-74.
18. Castle P, Sideri M, Jeronimo J, Solomon D, Schiffman M,. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007; 197: 356. e1-356. e6.
19. Kotaniemi-Talonen L, Malila N, Nieminen P, Anttila A, Tarkkanen J, Laurila P, et al. Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening. Int J Cancer 2008; 123: 2902-6.
20. Mesher D, Szarewski A, Cadman L, Cubie H, Kitchener H, Luesley D, et al. Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. Br J Cancer 2010; 102: 1405-10.
21. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, et al. Results at recruitment from a randomised controlled trial comparing Human Papillomavirus testing alone to conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100: 492-501.
22. Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, Belinson JL, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol 2010; 11: 1160-71.
23. Pretorius RG, Zhang WH, Belinson JL, Huang MN, Wu LY, Zhang X, et al. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 2004; 191: 430-4.
24. Pretorius RG, Belinson JL, Burchette RJ, Hu S, Zhang X, Qiao YL,. Regardless of skill, performing more biopsies increases the sensitivity of colposcopy. J Low Genit Tract Dis 2011; 15: 180-8.
25. Simoens C, Goffin F, Simon P, Barlow P, Antoine J, Foidart J, et al. Adverse obstetrical outcomes after treatment of precancerous cervical lesions: a Belgian multicentre study. BJOG 2012; 119: 1247-55.
26. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E,. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006; 367: 489-98.
27. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008; 18: 337: a1284.
28. Ortoft G, Henriksen T, Hansen E, Petersen L,. After conisation of the cervix, the perinatal mortality as a result of preterm delivery increases in subsequent pregnancy. BJOG 2010; 117: 258-67.
29. Zorzi M, Fedato C, Cogo C, Baracco S,. I programmi di screening oncologici del Veneto. Rapporto 2010. Padova: CLEUP, 2012. (Italian). [www.registrotumoriveneto.it/screening/presentazione.php]. Accessed 5 December 2012.